(Q46878669)

26 December 2017

title

Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma (English)

1 reference

26 December 2017

author name string

Emilio Bajetta

series ordinal

1

1 reference

26 December 2017

publication date

27 November 2007

1 reference

26 December 2017

Nature Clinical Practice Oncology

published in

1 reference

26 December 2017

volume

5

1 reference

26 December 2017

issue

1

1 reference

26 December 2017

page(s)

4-5

1 reference

26 December 2017

Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1007

7 January 2021

Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1007

7 January 2021

Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1007

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1007

7 January 2021

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1007

7 January 2021

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1007

7 January 2021

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1007

7 January 2021

Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1007

7 January 2021

Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1007

7 January 2021

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1007

7 January 2021

Identifiers

DOI

10.1038/NCPONC1007

1 reference

26 December 2017

1 reference

26 December 2017